1 10 48 https://ciencia.lugoneseditorial.com.ar/files/original/6b557998973ef330a313d5a6bf13e325.pdf 8364899a7975703c3ef38e7d8a210c6e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Why aren't all continuous glucose monitoring (CGM) systems the same? Description An account of the resource The FDA has developed a classification for CGM systems that divides them into those that require (complementary) or do not (non-complementary) the use of test strips for safe decision making. Source A related resource from which the described resource is derived 1. Campbell F. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatric Diabetes 2018; 19(7):1294-1301. doi: 10.1111/pedi.12735. Publisher An entity responsible for making the resource available María Fernanda Cristoforetti Date A point or period of time associated with an event in the lifecycle of the resource 14/03/2025 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0592">https://doi.org/10.47196/0592</a> Abbott Diabetes Advantages of Non-complementary CGM CGM CGM Classification Complementary CGM continuous glucose monitoring Diabetes Non-complementary CGM https://ciencia.lugoneseditorial.com.ar/files/original/738e4f94a76d1997b124c0a0e4747102.pdf d54e247e78243fec40b4b92732e8bbf6 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/diabetes/wegovy-obesidad/">https://lugoneseditorial.com.ar/diabetes/wegovy-obesidad/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Wegovy®: redefiniendo la historia de la obesidad Description An account of the resource Novo Nordisk presentará en Argentina su nuevo tratamiento para la obesidad, Wegovy® (semaglutida 2,4 mg), durante el encuentro virtual “Wegovy®: redefiniendo la historia de la obesidad”, que se realizará el 14 de octubre de 2025 a las 19 h. Creator An entity primarily responsible for making the resource Dra. Mónica Katz, médica especialista en Nutrición, Directora de la Diplomatura en Obesidad de la Universidad Favaloro y referente nacional en obesidad y nutrición clínica. Dra. Almudena Castro Conde, médica cardióloga, Jefa de la Unidad de Rehabilitación Cardíaca del Hospital Universitario La Paz (Madrid, España) y Coordinadora del Grupo de trabajo Diabetes y Obesidad de la Sociedad Española de Cardiología. Source A related resource from which the described resource is derived - Novoenred - Información de producto Wegovy. Certificado N° 59.900 Date A point or period of time associated with an event in the lifecycle of the resource 08/10/2025 obesidad semaglutida wegovy Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/destacada/rol-vacunas-diabetes/">https://lugoneseditorial.com.ar/destacada/rol-vacunas-diabetes/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource The role of vaccines in diabetes. Interview with Dr. Amadeo Esposto Description An account of the resource For people with diabetes, vaccines are highly valuable preventive tools against infections. The importance of spreading the value of immunization. Interview with Dr. Amadeo Esposto (M.N. 13891), Infectious Diseases Doctor, senior specialist in Internal Medicine, former head of the Infectious Diseases Service, San Martín de La Plata General Hospital. Creator An entity primarily responsible for making the resource Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Source A related resource from which the described resource is derived https://lugoneseditorial.com.ar/destacada/rol-vacunas-diabetes/ Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 27/04/2024 Contributor An entity responsible for making contributions to the resource Pfizer Amadeo Esposto Anti-flu Anti-pneumococcal COVID-19 Dengue Diabetes Hepatitis B Herpes Zóster Immunization RSV Vaccination schedule Vaccines Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/">https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Terapia oral innovadora para la psoriasis Description An account of the resource Con una alta eficacia y un perfil de seguridad favorable, deucravacitinib resulta una terapia oral innovadora para la psoriasis en placas de moderada a severa. Su vía oral es una gran ventaja y promete mejorar significativamente el manejo de la enfermedad. Creator An entity primarily responsible for making the resource Claudio Greco, Médico Dermatólogo, Miembro del Grupo de Psoriasis y Vitiligo de la Sociedad Argentina de Dermatología, Coordinador del Grupo de Hidradenitis Supurativa Source A related resource from which the described resource is derived I. Warren RB, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis. Psoriasis Area and Severity Index (PASI) outcomes over 4 years in patients receiving continuous deucravacitinib in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. II. Warren RB, et al. Deucravacitinib in plaque psoriasis. 4-year efficacy results by prior biologic treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. III. Thaçi D, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease. Response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rdEuropean Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. IV. Thaçi D, et al. Deucravacitinib efficacy in Psoriasis Area and Severity Index (PASI) target outcomes through 4 years in the phase 3 POETYK trials in moderate to severe plaque psoriasis Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. V. Gooderham MJ, Hong CH, Litvinov IV. Selective TYK2 inhibition in the treatment of moderate to severe chronic plaque psoriasis. Skin Therapy Letter 2022;27(6). VI. Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis. A network meta-analysis. Dermatology and Therapy. 2023 Nov;13(11):2839-2857. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 13/12/2024 Contributor An entity responsible for making contributions to the resource Bristol Myers Language A language of the resource Español Bristol Claudio Greco Deucravacitinib eficacia Perfil de seguridad Psoriasis Psoriasis en placa Terapia oral Infección por dengue en diabetes https://ciencia.lugoneseditorial.com.ar/files/original/79c4ff8d9000c953992b63315068be65.pdf 71c90734a4afcc4ce114c345c670c724 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/destacada/tecnologia-diabetes/">https://lugoneseditorial.com.ar/destacada/tecnologia-diabetes/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Tecnología aplicada a la diabetes Description An account of the resource En la 17º Conferencia Internacional del ATTD 2024 los temas centrales fueron el diagnóstico de diabetes tipo 1 en etapas preclínicas y los aportes de la tecnología en diabetes tipo 2. Además, el rol de la inteligencia artificial en las nuevas opciones de monitoreo. Creator An entity primarily responsible for making the resource Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Source A related resource from which the described resource is derived I. Martens T, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin. A randomized clinical trial. JAMA 2021;325(22):2262-2272. II, Carlson AL, et al. Flash glucose monitoring in type 2 patients managed with basal insulin in USA. BMJ Open Diabetes Res Care 2022;10(1):e002590. III. Guerci B, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther 2023 Jan;25(1):20-30. IV. Miller E, et al. FreeStyle Libre improves HbA1c in people receiving GLP-1 therapy for type 2 diabetes. ATTD Conference, March 6-9, 2024, Florence, Italy. V. Wright E, et al. Initiating GLP-1 therapy in combination with FreeStyle Libre provides greater benefit compared to GLP-1 alone. ATTD Conference, March 6-9, 2024, Florence, Italy. VI. Choe HG, et al. Effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring in patients with type 2 diabetes. Results from the randomized open-label PDF study. Diabetes Care 2022;45(10):2224-2230. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 8 abril, 2024 Contributor An entity responsible for making contributions to the resource Sanofi Rights Information about rights held in and over the resource Sello Editorial Lugones Relation A related resource https://lugoneseditorial.com.ar/destacada/tecnologia-diabetes/ Format The file format, physical medium, or dimensions of the resource Digital Language A language of the resource Español Type The nature or genre of the resource Artículo científico Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0577" target="_blank" rel="noreferrer noopener">https://doi.org/10.47196/0577</a><span></span><span class="dropdown"><a class="dropdown-toggle" href="https://search.crossref.org/?from_ui=&amp;q=Tecnolog%C3%ADa+aplicada+a+la+diabetes#"><i class="icon-double-angle-down"></i></a></span> ATTD 2024 Diabetes Inteligencia artificial Sanofi Teconología https://ciencia.lugoneseditorial.com.ar/files/original/4fce8859c24f9299717fde9f0f03b0fe.pdf 71c90734a4afcc4ce114c345c670c724 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/destacada/tecnologia-diabetes/">https://lugoneseditorial.com.ar/destacada/tecnologia-diabetes/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Technology applied to diabetes Description An account of the resource At the 17th International Conference of ATTD 2024, the central topics were the diagnosis of type 1 diabetes in preclinical stages and the contributions of technology in type 2 diabetes. In addition, the role of artificial intelligence in new monitoring options. Creator An entity primarily responsible for making the resource Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Source A related resource from which the described resource is derived I. Carlson AL, et al. Flash glucose monitoring in type 2 patients managed with basal insulin in USA. BMJ Open Diabetes Res Care 2022;10(1):e002590. II. Guerci B, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther 2023 Jan;25(1):20-30. III. Miller E, et al. FreeStyle Libre improves HbA1c in people receiving GLP-1 therapy for type 2 diabetes. ATTD Conference, March 6-9, 2024, Florence, Italy. IV. Wright E, et al. Initiating GLP-1 therapy in combination with FreeStyle Libre provides greater benefit compared to GLP-1 alone. ATTD Conference, March 6-9, 2024, Florence, Italy. V. Choe HG, et al. Effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring in patients with type 2 diabetes. Results from the randomized open-label PDF study. Diabetes Care 2022;45(10):2224-2230. Artificial intelligence ATTD 2024 Diabetes Sanofi Technology https://ciencia.lugoneseditorial.com.ar/files/original/d917f48efc9817f0e90e9bca5ef43ffe.pdf fca41daa9e2aeeea547aff1d1c9010d9 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Safety and efficacy study of cross-linked hyaluronic acid filler in nasolabial folds Subject The topic of the resource <em>Dermatology</em> Description An account of the resource <strong>Introduction</strong>: facial aging causes cellular and anatomical changes, resulting in loss of soft tissue volume. Due to aesthetic demand, hyaluronic acid is a very good option for filling facial folds and wrinkles. <strong>Objectives</strong>: verify the effectiveness and safety of the application of cross-linked hyaluronic acid (CLHA) for filling nasolabial folds and its permanence over time. <strong>Design</strong>: observational and descriptive clinical, longitudinal and prospective, 12 months long. Materials and methods: a total of 100 patients (86 women and 14 men) with moderate to severe nasolabial folds were studied between July 2018 and December 2019. CLHA 30 mg/ml was used for facial filler (Estrianon Hyaluronic Implant 30®, Allanmar International Company S.R.L., Argentina) <strong>Results</strong>: the adverse effects subsided within 7 days in 97% of the patients and in the rest of the patients within 14 days. The initial application was up to 1 ml per groove in the most severe cases. Regarding its effectiveness as a filler, its average duration was found to be up to 8 months with the corresponding reapplications. <strong>Conclusions</strong>: Estrianon Hyaluronic Implant 30® is a safe product, its duration depends largely on the age of the patient, their habits and the condition of their skin, exceeding 8 months and up to a year. Creator An entity primarily responsible for making the resource <span>Editora: María Fernanda Cristoforetti</span> Source A related resource from which the described resource is derived I. Scardovi S, Goglian A, Gendra P, Gendra C. Clinical study of the efficacy, duration and adverse effects of hyaluronic acid implants in the oral-maxillofacial área. Odontoestomatol 2017;19(30):78-91. doi: 10.22592/ o2017n30a9. II. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers: The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. III. Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Advanced concepts in rheology for the evaluation of hyaluronic acid-based soft tissue fillers. Dermatol Surg. 2021 May 1;47(5):e159-e167. doi: 10.1097/ DSS.0000000000002916. IV. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/ files/Hialuronico%20y%20efectos%20adversos%20-%20 Dras.%20Cifuentes%20y%20Signes.pdf. V. Snibson GR, Greaves JL, Soper ND, Prydal JI, Wilson CG, Bron AJ. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye (Lond) 1990;4 (Pt 4):594-602. doi: 10.1038/eye.1990.83. VI. Sourdille P, Santiago PY, Villain F, Yamamichi M, Tahi H, Parel JM, Ducournau Y. Reticulated hyaluronic acid implant in nonperforating trabecular surgery. J Cataract Refract Surg 1999 Mar;25(3):332-9. doi: 10.1016/s08863350(99)80080-7. VII. He Z, Han S, Zhen Z, Ding X, Liang S. The clinical use of sodium hyaluronate eyedrops as a substitute for tears. Yan Ke Xue Bao 1990 Dec;6(3-4):111-2. VIII. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, doubleblind, placebo-controlled clinical trial. Arch Intern Med 2002 Feb 11;162(3):292-8. doi: 10.1001/archinte.162.3.292. IX. Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002 Jul;10(7):506-17. doi: 10.1053/joca.2002.0798. X. Tamer TM. Hyaluronan and synovial joint: function, distribution and healing. Interdiscip Toxicol 2013 Sep;6(3):111-25. doi: 10.2478/intox-2013-0019. XI. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998 Nov;25(11):220312. Erratum in: J Rheumatol 1999 May;26(5):1216. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg. 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. Ågerup B, Wik O. The MonographnashaTM. 2008. Disponible en: https://docplayer.net/20739410-Nashathe-monograph-1.html. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plást Iberolatinoam 2011;37(4):393-402. XVI. Smith SR, Jones D, Thomas JA, Murphy DK, Beddingfield FC. Duration of wrinkle correction following repeat treatment with Juvéderm hyaluronic acid fillers. Arch Dermatol Res 2010 Dec;302(10):757-62. doi: 10.1007/ s00403-010-1086-8. XVII. Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, Lin V, Murphy DK. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds. Results of a randomized, controlled study. Dermatol Surg 2018 May;44(5):670-678. doi: 10.1097/ DSS.0000000000001529. XVIII. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XIX. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XX. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XXI. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. XXII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XXIII. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm versus Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J. 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. Publisher An entity responsible for making the resource available <em>Editorial Lugones</em> Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource <em>Allanmar International Company S.R.L</em> Rights Information about rights held in and over the resource Legal records: Lugones® Editorial Seal. Director: Facundo Lugones. Editor: Lic. María Fernanda Cristoforetti. Owner: Editorial Biotecnológica S.R.L. Legal address: Av. Curapaligüe 202, 9° B (1406), City of Buenos Aires, Argentina. Authors of the Lugones article Editorial: Marcelo Robles. Reproduction rights: Lugones® Editorial Seal, Editorial Biotecnológica S.R.L. Total or partial reproduction of the articles is prohibited without the authorization of the author and the publisher. Work registered in the National Directorate of Copyright, Ministry of Justice and Human Rights of the Argentine Republic. Registration of Published Work-Web Page in File No.: RL-2021-41251755-APN-DNDA#MJ. Registration of Periodical Publications in File No.: RL-2023-71140630-APN-DNDA#MJ, City of Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource Spanish and english Type The nature or genre of the resource Scientific Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/">https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant <em>Argentina, 2023</em> hyaluronic acid crosslinked nasolabial folds skin aging https://ciencia.lugoneseditorial.com.ar/files/original/4a5c3d9e621a089ad33eee26e6893a90.pdf 41e2681074196163f89f9fe9d560d364 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/dermatologia/desbridamiento-pie-diabetico/">https://lugoneseditorial.com.ar/dermatologia/desbridamiento-pie-diabetico/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Pie diabético: desbridamiento enzimático Description An account of the resource Entrevista con la Dra. Mabel Carrió (M.N. 68739), Médica Diabetóloga, Directora del Centro Municipal de Diabetes Dr. Alberto Maggio y del Hospital de Día de Pie Diabético Malvinas Argentinas, Directora de la Diplomatura de Pie Diabético, Universidad Nacional del Nordeste (UNNE) La colagenasa se emplea para realizar el desbridamiento enzimático en casos de úlceras del pie diabético dado que facilita una transición adecuada entre las distintas fases de cicatrización Creator An entity primarily responsible for making the resource Entrevista con la Dra. Mabel Carrió (M.N. 68739), Médica Diabetóloga, Directora del Centro Municipal de Diabetes Dr. Alberto Maggio y del Hospital de Día de Pie Diabético Malvinas Argentinas, Directora de la Diplomatura de Pie Diabético, Universidad Nacional del Nordeste (UNNE) Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 17/11/2025 Contributor An entity responsible for making contributions to the resource Iruxol - Abbott Abbott Iruxol 3 Beneficios colagenasa Colagenasa Desbridamiento enzimático Fases de cicatrización Mabel Carrió pie diabético Úlceras del pie diabético Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Monitoreo continuo de glucosa: nuevo portal de diabetes Description An account of the resource En el nuevo Portal Abbott Diabetes destacados especialistas dictan cursos certificados y on demand sobre los últimos avances en monitoreo continuo de glucosa y tecnología aplicada a la diabetes. Exclusivo para profesionales de la salud. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 16 diciembre, 2024 Contributor An entity responsible for making contributions to the resource Abbott Diabetes Adrián Proietti Alejandro Dain Aspectos clave del uso del monitoreo continuo de glucosa Cursos certificados Cursos on demand Diabetes Florencia Siufi FreeStyle Libre Gabriela Rovira Laura Kabakian LibreView María Ruiz monitoreo continuo de glucosa Portal Abbott Diabetes Portal médico Tecnología aplicada a la diabetes https://ciencia.lugoneseditorial.com.ar/files/original/a722a992e3188d3b542d1f7408ad2425.pdf 706d8ebce706d0dcecbe09b3f98cb768 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-labios/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-labios/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Lip volumization with cross-linked hyaluronic acid 18 mg/ml. Efficacy and safety in 102 treated patients Description An account of the resource Introduction: beauty trends have increased the demand for aesthetic procedures, especially the use of hyaluronic acid (HA), to rejuvenate the face and enhance lips. This safe and effective treatment hydrates, fills wrinkles, and restores volume to different areas of the face. HA is obtained from non-animal sources, is non-immunogenic, and possesses antioxidant properties. The perioral region, key to facial aging, is highly sought after for correcting wrinkles, folds, and the loss of definition caused by factors such as age, sun exposure, and lifestyle habits. Cross-linked hyaluronic acid (HRA) is an ideal option for restoring volume to this area. Objectives: to evaluate the safety, efficacy and adverse effects of using HRA 18 mg/ml as a lip filler. Materials and methods: a prospective clinical study included 102 patients (81 women and 21 men), aged 25–65, who required lip volumization and received Cientific Hyaluronic Facial Implant 18® (HRA 18 mg/ml). Treatment efficacy was assessed using the Global Aesthetic Improvement Scale (GAIS). Initial lip volume and perioral wrinkle severity were assessed using the photonumeric scales MERZ (Merz Lip Fullness Scale, MLFS) and Wrinkle Severity Rating Scale (WSRS), respectively. Safety was determined by analyzing local reactions at the injection site and the occurrence of adverse events. The product was administered at a dose of up to 1 ml per half of the lip in an initial application (T0), with follow-ups at 1, 3, and 8 months. If necessary, a single reapplication was performed during these follow-ups. Treatment efficacy was assessed at a final follow-up at 12 months. Results: adverse effects were mild, of immediate onset, common for this type of treatment, which resolved without the need for special treatment. The volumizing effect of HRA 18 mg/ml was effective in 98% of treated patients, with a gradual decrease after 12 months. A significant improvement in lip hydration and firmness was observed. Conclusions: HRA 18 mg/ml is a safe and effective treatment as a dermal filler in lips, with high volume retention and lasting up to 12 months. Patients and professionals experienced high satisfaction, and improvements in skin firmness and elasticity were observed. The results support HRA as a viable and beneficial option in aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky Date A point or period of time associated with an event in the lifecycle of the resource 12/05/2025 Contributor An entity responsible for making contributions to the resource Allanmar Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0595">https://doi.org/10.47196/0595</a> hyaluronic acid lips perioral area volumization